Compare OSUR & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSUR | FDMT |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.9M | 479.9M |
| IPO Year | 2000 | 2019 |
| Metric | OSUR | FDMT |
|---|---|---|
| Price | $3.03 | $10.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $3.00 | ★ $31.71 |
| AVG Volume (30 Days) | 433.0K | ★ 645.5K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $167,064,000.00 | $85,209,000.00 |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | $7.76 | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $2.08 | $3.03 |
| 52 Week High | $3.76 | $12.34 |
| Indicator | OSUR | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 58.85 |
| Support Level | $2.87 | $9.71 |
| Resistance Level | $3.25 | $10.70 |
| Average True Range (ATR) | 0.13 | 0.59 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 43.41 | 71.21 |
OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).